KLK3 and neutropenia: The results of this study indicated that EA reduced chemotherapy-associated myelotoxicity, in particular neutropenia, and induced a marked decrease in prostate-specific antigen (PSA) levels in a higher percentage of patients compared to chemotherapy alone.